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Effects of Chronic Topical Application of
12-O-Tetradecanoylphorbol-13-acetate on
the Skin and Internal Organs of SENCAR
Mice
by Andres J. P. Klein-Szanto,*§ Claudio J. Conti,*
Claudio M. Aldaz,* Neal Clapp,t Stephen Nesnow,** and
Thomas J. Slaga*
Repetitive topical applications of 2 ,ug 12-0-tetradecanoylphorbol-13-acetate (TPA) twice weekly for 37
to 52 weeks induced a sustained epidermal hyperplasia, hyperplasia ofhair follicles, and increased dermal
cellularity in SENCAR mice. In addition, after 52 weeks of protracted promoter treatment most animals
developed generalized amyloidosis involving liver and spleen, as well as interstitial nephritis. Severe
pyelonephritis and papillary necrosis were also frequently seen. Reactive lymphoid hyperplasia was also
a frequent finding. Chronic administration of TPA is not an innocuous treatment affecting only the
interfollicular epidermis. The general effect of the promoter on the animals was a marked decrease in
their longevity, probably through impairment ofthe immune system.
Introduction
The in. vivo effects of tumor promoters, especially
those produced by topical application ofa single dose of
12-0-tetradecanoylphorbol-13-acetate (TPA), have
been extensively described (1-7). The study of the ef-
fects of multiple repetitive applications of TPA on ini-
tiatedskin, theonlyscheduleofadministrationresulting
in significant tumorproduction, has been partially stud-
ied by a few investigators (8-10). Even less is known
about the systemic effects of TPA when animals are
subjected to protracted promoter treatments.
In two separate studies we have analyzed the effects
ofchronic, topical applications of 2 pug TPA on the un-
initiated skin and otherorgans ofSENCAR miceduring
37 to 52 weeks ofrepetitive twice-weekly treatments.
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Effects of 74 TPA Applications on
Mouse Skin
Epidermal Hyperplasia
The effects ofrepetitive treatments ofTPA on mouse
skin were studied using 3HTdr pulse labeling and mor-
phometric techniques. A sustained marked epidermal
hyperplasia (4 to 5 times normal values) (Figs. 1 and 2)
was a constant feature duringchronic exposure to TPA.
Only 5% of the animals developed papillomas (with a
maximum of two papillomas/animal), and none devel-
oped carcinomas. The percentage of dark cells, the la-
belingindex ofthe basallayer, and the epidermal thick-
ness during chronic TPA treatment are shown in
Figures la and lb. The pattern ofthe curves is similar;
both show anearlypeakafterfourtreatments, descend-
ing slightly thereafter. The epidermal thickness values
correlated well with number of nucleated cell layers
(data not shown) indicating that the increase seen in
thefirstportionofthecurvewasnotduetoedemaalone.
Although an early peak was not seen, the number of
hair follicles per length of epidermal surface increased
and also reached equilibrium after the eighth TPA ap-
plication (Fig. lc).KLEIN-SZANTO ET AL.
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FIGURE 1. Morphometric data of epithelial structures of the skin:
(a) percentage oflabeled basal cells and percentage of dark basal
keratinocytes; (b) epidermal thickness; (c) number ofhair follicles.
From Aldaz et al. (10) with permission.
Cellular Changes in the Dermis
The total dermal thickness increased immediately
after beginning TPA application. This initial increase of
FIGURE 2. Epidermalhyperplasia after74 applicationsof2 ,ugTPA.
approximately 50% was evident after four TPA treat-
ments (Fig. 3a) and was attributed to edema and acute
inflammation. Later on, an additional gradual increase
was observed. This increase of dermal thickness ob-
served after 40 TPA applications was due to the pro-
duction ofafibrotic dermis. The total dermal cellularity
increased with the number of treatments, reaching a
plateau after the eighth application (Fig. 3b). The rel-
ative proportion ofthe different cellular types changed
during the course ofthe treatment. After the first TPA
application, the two predominant cellular types were
the polymorphonuclear leukocytes and the fibroblasts.
The number of polymorphonuclear leukocytes dropped
dramatically during the first weeks of treatment. The
lymphocytes increased from 2.4% in controls to 15.7%
on the eighth application. The macrophages, also in-
volved in the chronic inflammatory reaction, increased
slowly during treatment. The number ofmast cells was
always higher than that in the control tissues (Fig. 3c).
During the latter part of the chronic treatment, an in-
crease offibroblasts and capillary vessels was observed.
Effects of 104 TPA Applications on
Mouse Skin
Figure4showsthe survivalofSENCAR micetreated
with 1- and 2-,ug doses of TPA. After 12 months it
became obvious that topical treatment with this tumor
promoter, especially with 2-,ug doses was markedly le-
thal, approximately equivalent to an LD50.
The general characteristics of the cutaneous altera-
tions were the same as those after80 treatments. How-
ever, some additional changes were observed. In some
animals, cystic dilatations and atrophic changes were
observed in the hair follicles, resulting in a few cases
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FIGURE 3. Morphometric evaluation of TPA-induced dermal
changes: (a) dermal thinkness from basement membrane to the
subcutaneous adipose tissue; (b) total dermal cellularity per mi-
croscopic field; (c) number of mast-cells per length of epidernal
surface. From Aldaz et al. (10) with permission.
in the formation of epidermoid cysts of 1- to 10-mm
diameter. In addition, and related to the same phenom-
enon, we could observe the presence of multiple kera-
tinic granulomas in the superficial dermis ofsix animals
(Fig. 5). In seven animals out of75, marked hyaline and
or amyloid changes of the papillary dermis could be
seen. Cutaneous ulcers, sometimes exhibiting exuber-
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FIGURE 4. Survival curves ofSENCAR mice treated topically with
TPA.
ant granulation tissue, were also observed. In these
cases, as well as in a few others without ulceration,
regional lymph nodes showed changes ofinterfollicular
and/or follicular hyperplasia (Table 1).
Effects of 104 TPA Applications on Other
Organs
Table 2 summarizes the general findings after 52
weeks of treatment. Generalized amyloidosis was the
most frequently encountered alteration (62% of ani-
mals); the liver and spleen were always affected (Fig.
6); kidneys were frequently involved; and adrenals,
skin, and intestines contained occasional amyloid de-
posits. Chronic focal interstitial nephritis was very fre-
quently seen (60%) and in some cases exhibited a clear
picture ofchronic pyelonephritis. In several cases a ne-
phropathy involving all kidney elements, including glo-
merular fibrosis and interstitial chronic inflammation,
could be seen. Papillary necrosis (Fig. 7) accompanied,
very frequently, the most advanced cases of nephritis
and/or renal amyloidois. Systemic lymphadenopathies,
mainly ofinguinal, axillary, mesenteric, andmediastinal
nodes, were observed in many animals. In most cases,
the normal lymph mode architecture was conserved,
and only a reactional (hyperplastic) chronic lymphad-
enitis could be recognized. However, in several cases,
especially in those with cutaneous erosions and/or ul-
cers, a more dramatic picture with total or partial ef-
facement ofthe node architecture was observed. These
alterations, consistent with the diagnosis of dermato-
pathic lymphadenopathy, were enlargement of para-
cortical areas due to the presence of histiocytes and
activated lymphocytes.
In 37% ofthe animals, chronic adenitis with marked
proliferation of endothelial cells and capillary vessels,
as well as the presence of large, sometimes atypical,
20-
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Table 2. Pathology of animals killed after 104 TPA applications.
Males, % Females, %
Liver and spleen amyloidosis 63 61
Interstitial nephritis and pyelonephritis 67 54
Papillary necrosis 34 35
Adenopathies (reactive hyperplasia) 40 35
Skin papillomas 4 19
Skin carcinomas 4 0
Lung adenomas 4 4
noma ofthe skin were seen after 104 TPA applications,
this frequency was not significantly different from the
spontaneous incidence of malignant skin tumors found
.g i :;iin a control group (Table 3). Similarly, no differences
were found in the incidence of neoplasias of the lung
and hematopoietic organs.
.~~ Discussion
Except forthe casesthatexhibited ulcers orerosions,
repetitive treatment of skin with promoting doses of
TPA produces a steady-state epidermal hyperplasia
with an increased dermal cellularity. Most dermal cells
werefibroblasts and endothelialcells, resultingin avery
dense and hypervascularized dermis. It is interesting
to note that most authors have focused on the hyper-
plasiogenic effects of TPA on the epidermis and have
overlooked cell proliferation in the dermis. Similarly,
with the exception of one group ofinvestigators (9), the
t t ; g S effects ofpromoters on hair follicles were not studied.
. .-.i* We were able to confirm, with a different technique,
E,; i " j:0 the induction of new hair follicles described in whole-
FIGURE 5. Dermal keratinic granuloma with giant cell reaction
around horny squames, after 104 applications of 2 pg TPA.
lymphocytes, plasma cells, and immunoblasts, was seen
(Fig. 8). This histological picture is similar to that of
angioimmunoblasticlymphadenopathy, ahumandisease ~ ~
characterized by hyperproliferation of B-cells. In two
other cases we have seen a similar picture, including
cell destruction, presence of polymorphonuclear leu-
kocytes, actively phagocytic macrophages, and mitosis.
Frequently these alterations were accompanied by in- C
tranodal foci of extramedullary hematopoiesis. Al- .
though a few benign tumors and one squamous carci-
Table 1. Percent of animals with skin ulcers and reactive
lymphadenopathies.
Males Females___
Died Killed after Died Killed after
before 1 104 TPA before 1 104 TPA
year applications year applications
Lymphadenopathies 45 70 57 71 F.e
Skin ulcers 45 18 28 3 FIGURE 6. Liver amyloidosis after 104 treatments of 2 I.g TPA.
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FIGURE 7. Papillary necrosis seen in the kidney with chronic pye-
lonephritis after 104 TPA applications.
mounts of TPA-treated skin (9). From these state-
ments, it is easy to conclude that the interfollicular ep-
idermis is not the only target ofTPA. The hair follicles,
as well as the dermal components, are fully affected by
the promotertreatment. Hairfollicles havebeensingled
out very frequently as the origin of cutaneous tumors,
including papillomas. The effects ofthe mesenchyme on
the differentiation ofthe epidermis, as well as the pos-
sible role ofhairfollicles, areimportant factsthat should
be considered in the pathogenesis oftumors induced by
two-stage carcinogenesis in SENCAR mice.
Skin ulcers were seen in many animals after 104 TPA
applications and were always accompanied by regional
and, sometimes, distant reactive lymph node hyperpla-
sia. This lymph node reaction, although especially evi-
dent in these cases, was also seen in most animals with-
out cutaneous ulcers. Table 3 shows that the majority
of animals exhibited lymphadenopathies, but only the
males exhibited skin ulcers, probably related to biting
and fighting. Consequently, it is more than feasible that
the reactive lymphadenitis seen in most ofthese animals
is not due to secondary inflammation but is due to the
effect of TPA.
The histopathology of lymph node lesions was not
uniform. Although all lesions showed components of
chronic reactive lymphadenitis, they also included foci
of extramedullary myelopoiesis and angioblastic prolif-
eration, as well as the presence ofhistiocytes and atyp-
FIGURE 8. Reactive lymphoid tissue hyperplasia with effacement of
the normal lymph node architecture after 104 applicatons ofTPA.
Note numerous blood vessels.
ical lymphocytes. Some of these alterations were com-
patible with lesions observed in human immune system
dysfunctions, such as those seen in acquired immuno-
deficiency syndrome (11), dermatopathic lymphadenop-
athy (12,13), and angioimmunoblastic lymphadenopathy
(14,15). TPA has been shown to modify the response of
murine T-lymphocytes and macrophages (16) and to in-
duce the proliferation of the granulocyte macrophage
precursor cells (17). Consequently, the lymph node al-
terations seen in our animals might indicate a direct
effect of TPA on lymph node architecture and function
that warrants further study.
Another probable evidence of a immunological dis-
turbance isthegeneralized amyloidosis seenintheliver,
spleen, and kidney ofmost animals and occasionally also
observed in the skin, intestines, and other organs. Al-
though the distribution oftheamyloiddeposits coincides
Table 3. Skin tumors in SENCAR mice.
Animals Animals
with Papillo- with Carcino-
papillo- mas per corcino- mas per
Treatment Sex N mas mouse mas mouse
None M 127 0 0 4 0.03
F 220 1 0.004 0 0
104 TPA M 27 1 0.04 1 0.04
(2pg) F 26 5 0.23 0 0
treatments
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with the secondary (AA) type (18), an accelerated form
of systemic senile amyloidosis (AS/SAM) as described
by Takeda and colleagues (19) cannot be excluded. This
possibility is enhanced by the fact that untreated 18- to
30-month old SENCAR mice are frequently affected by
generalized amyloidosis. It is also worthwhile to note
that papillary necrosis seen in 35% ofTPA-treated an-
imals was described in another mouse strain with renal
amyloidosis (20). Interstitial nephritis and chronic pye-
lonephritis were seen in most animals after prolonged
TPA treatment. Whether this effect is primary and di-
rectly related to an eventual nephrotoxic property of
TPA or secondary, as is more probably the case, re-
mains to be investigated.
Althoughsomeauthorshavedescribedtheproduction
of a significant number of skin tumors in mice treated
with TPA alone (21,22), we have not been able to find
differences between the incidence ofcarcinomas in un-
treated and TPA-treated SENCAR mice. Although
TPAincreasedthe levelofpapillomas seenin SENCAR
mice, thepapillomayieldwas0.23papillomaspermouse
in females and 0.04 papillomas per mouse in males. It
has to be pointed out that the tumor yield in initiated
animals is much higher, i.e., 7 papillomas/mouse at 15
weeks (23).
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